Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 3 2009 09 15 17 20 Amir Ali Hamidieh Pediatric Hematology- Oncology and Stem Cell Transplantation Department, Hematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran B Moradbeag Faculty of Medicine, Qom Islamic Azad University, Qom, Iran F Pasha Faculty of Medicine, Tehran Islamic Azad University, Tehran, Iran Mehdi Jalili Pediatric Hematology- Oncology and Stem Cell Transplantation Department, ematology- Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran M Hadjibabaie Clinical Pharmacology Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran M Keshavarznia Faculty of Medicine, Qom Islamic Azad University, Qom, Iran 2015 10 01 Introduction: Hypoparathyroidism (HPT) is an irreversible but preventable disorder caused by an iron overload which can be considered a typical complication in patients with beta-thalassemia major. Patients and method: Parathyroid function was evaluated in 130 patients in Qom, Iran, who suffered from beta-thalassemia major. Their serum ferritin levels were checked for monitoring of chelation therapy effects. Results: The prevalence of HPT was 14.6% (19/130). The median age of patients with HPT was significantly higher than of patients without HPT (18 vs. 15 years; P=0.03). Serum ferritin levels was not significantly different between the two groups (median: 2709 vs. 1512; P=0.95). The prevalence of cardiac diastolic dysfunction in patients with HPT was significantly higher than in normal thalassemic patients (3.1% vs. 15.8%, P=0.04). Patients with hypoparathyroidism demonstrated abnormal glucose metabolism (0% vs. 15.8%; P=0.003). Conclusion: the high prevalence of hypoparathyroidism demonstrated poor chelation therapy in these patients. Close monitoring of ferritin level was recommended. Also, the measurement of parathyroid hormone on a regular basis for all thalassemic patients was recommended. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/219 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/219/212